Matthew graduated from North Carolina State University in 2016 with his B.S. in Chemistry. As an undergraduate, he worked with Dr. Joshua Pierce on the total synthesis of alotamide A with applications to chemical probes for neurological disease. Further, Matthew conducted a summer research fellowship at Memorial Sloan Kettering Cancer Center under the direction of Dr. Derek Tan, in which he focused on the development of a synthetic method towards benzannulated medium-sized ring scaffolds. Matthew joined the Hergenrother lab in December of 2016 as a NIH Chemistry-Biology Interface fellow and Roger Adams Fellow. His work is focused on the synthesis and discovery of novel mutation-specific cancer therapeutics.
More on Matthew’s LinkedIn Profile
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
Janin M.; Ortiz-Barahona V.; Boudreau M.W.; Hergenrother P.J.; Esteller M. and others
Acta Neuropathol. 2019, 138, 1053-1074
Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential
Boudreau, M. W.; Peh, J.; Hergenrother, P. J.
ACS Chem. Biol. 2019, 14, 2335-2348
Overcoming resistance to targeted anticancer therapies through small-molecule mediated MEK degradation
Peh, J.; Boudreau, M. W.; Smith, H. M.; and Hergenrother, P. J.
Cell Chem. Biol. 2018, published on web June 14, 2018.